Preclinical Alzheimer’s Disease Studies

Expert Preclinical Alzheimer’s Disease Studies for Your Novel Treatment

At PsychoGenics, our experienced scientists provide expert preclinical Alzheimer’s disease (AD) studies to develop your therapy. Our research focuses on key pathological features of Alzheimer’s disease, including neurofibrillary tangles and amyloid plaques, which are widely thought to play a major role in disease progression.

Our Animal Models of Alzheimer’s Disease

Our expertise in Alzheimer’s disease models enables us to select the most appropriate models for specific research needs: 

This inducible tauopathy mouse model, rTg4510, overexpresses human P301L-mutant tau in the forebrain. By utilizing the tetracycline-controlled transactivator (tTA) system, combined with the CaMKII α promoter, this model recapitulates tau pathology observed in Alzheimer’s disease. This model shows cognitive deficits, neuroinflammation, and increased NF-L in plasma and CSF.

The APP/PS1 double transgenic mouse model overexpresses mutated forms of the genes for human amyloid precursor protein (APPsw) and presenilin 1 (m146L). This model allows us to study the progressive amyloid deposition observed in Alzheimer’s disease, providing insights into the disease’s development.

Partnering for Your Preclinical Alzheimer’s Disease Breakthrough

At PsychoGenics, we are dedicated to making significant strides in preclinical Alzheimer’s disease research. Our commitment to improving the lives of those affected by this devastating disease drives us to push the boundaries of knowledge and develop transformative therapies.

Explore Our Research

Explore our areas of neurodegenerative disease specialization:

Partner with PsychoGenics

and discover your next breakthrough

Get Started